Related Experiment Video
Updated: Oct 26, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex
M Hanada1, S Mizuno, A Fukushima
1Discovery Research Laboratories II, Sumitomo Pharmaceuticals Co., Ltd., Osaka.
Abstract:
Amrubicin is a novel, completely synthetic 9-aminoanthracycline derivative. Amrubicin and its C-13 alcohol metabolite, amrubicinol, inhibited purified human DNA topoisomerase II (topo II). Compared with doxorubicin (DXR), amrubicin and amrubicinol induced extensive DNA-protein complex formation and double-strand DNA breaks in CCRF-CEM cells and KU-2 cells. In this study, we found that ICRF-193, a topo II catalytic inhibitor, antagonized both DNA-protein complex formation and double-strand DNA breaks induced by amrubicin and amrubicinol. Coordinately, cell growth inhibition induced by amrubicin and amrubicinol, but not that induced by DXR, was antagonized by ICRF-193. Taken together, these findings indicate that the cell growth-inhibitory effects of amrubicin and amrubicinol are due to DNA-protein complex formation followed by double-strand DNA breaks, which are mediated by topo II.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Inhibition of Cdk Activity
Abnormal Proliferation
Treatment Resistant Cancers